Gocovri (amantadine) more than doubled the daily time on levodopa-based therapies without any dyskinesia — involuntary, uncontrolled movements — in people with Parkinson’s disease compared to those given a placebo, an analysis of data from two Phase…
News
In light of Parkinson’s Awareness Month — starting April 1st — Parkinson Canada is calling for better awareness of the neurodegenerative disorder, while supporting organizations dedicated to helping those impacted by it. This message is made more urgent by COVID-19, according to…
Activities are underway to mark Parkinson’s Awareness Month, set aside each April to draw attention to the neurodegenerative disorder that affects some seven to 10 million people globally. At the center of this observance is World Parkinson’s Day April 11. Patients, family, caregivers and friends across the country…
Several microRNAs in the blood of people with Parkinson’s disease differ from healthy controls, correlate with disease progression, and are associated with hallmarks of the disorder, a large-scale study reported. These findings support the possible use of microRNAs as biomarkers in…
More than 350 disease advocates, representing all 50 U.S. states, took part in The Michael J. Fox Foundation (MJFF) virtual Parkinson’s Policy Forum, urging lawmakers to increase federal investment in Parkinson’s disease (PD) research after years of stagnant support. Annual funding for the Department of Defense’s Parkinson’s Research…
A protein fragment known as GPR37 is evident in the cerebrospinal fluid of people with Parkinson’s disease, and may be promising candidate as a biomarker for earlier diagnosis, scientists in Spain announced. This fragment at high levels was found to be specific to the cerebrospinal fluid (CSF; the liquid surrounding…
The National Institutes of Health (NIH) has awarded a $5 million grant to researchers investigating whether an artificial intelligence tool might improve the accuracy of diagnosing Parkinson’s disease at its early stages. Early diagnosis is challenging due to the overlap of Parkinson’s motor and non-motor symptoms and those of two…
A University of Alberta pharmacology professor and researcher will use a CA $1.04 million grant to investigate the potential role of fatty molecules — called gangliosides — in treating neurodegenerative diseases, including Parkinson’s disease. The grant, from the Canadian Institutes of Health Research (CIHR) and worth about $826,000, was…
Regular dental visits and routine tooth brushing with alternating hands are among recommendations for better oral health in people with Parkinson’s disease, researchers report. Tooth decay and receding gums are known problems for these patients, and often overlooked due to the nature of this neurodegenerative disorder, the team noted. The paper,…
Forest Hills Lab announced plans to soon apply to the U.S. Food and Drug Administration (FDA) for permission to open a Phase 2 clinical trial evaluating the tolerability and efficacy of FHL-301 in people with Parkinson’s disease. FHL-301, or FHL CB-301, is reported to be a repurposed therapy…
Recent Posts
- New delivery system guides curcumin to Parkinson’s-affected brain cells
- New $2M MJFF grant backs Parkinson’s walking study at Boston University
- My fear of falling has gotten worse since my Parkinson’s diagnosis
- New compound targets mitochondrial damage in Parkinson’s models
- Environmental factors may impact Parkinson’s disease risk: Dutch study